Developer docs
API playgroundTry for free, no card

Search company profiles

TheraSyn Bio

Full company profile

uuid002b3hn

Namestring
TheraSyn Bio
Legal namestring
TheraSyn Bio Inc
Websiteurl
therasynbio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

TheraSyn Bio (TSB) is a Massachusetts-incorporated, privately held synthetic biology company founded in 2022 and headquartered in Lawrence, near the Cambridge innovation corridor. It operates an Integrated Bioscience Innovation Platform that the company describes as combining synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational bioscience research. The platform spans three stated pillars: Patient Therapies, Environmental Science, and Agriscience. The company's flagship initiative is Project Panacea, a preclinical program developing a localized, topical precision therapy for breast cancer intended to improve therapeutic efficacy while reducing systemic toxicity. Project Panacea is being advanced through a joint venture with Rubix LS, which contributes real-world patient data and clinical research expertise, while TSB contributes bioengineering capabilities. The company is explicitly pre-commercial: no products are approved or generating revenue, no funding rounds are disclosed, and headcount is reported in the 1-10 range.

TheraSyn Bio's commercial posture is enterprise-led and partnership-driven rather than product-sales-driven. Revenue mechanics, as disclosed, contemplate two streams: (i) therapeutic development and licensing, where Project Panacea and successor programs could be licensed to pharmaceutical partners, and (ii) platform services and partnerships, through collaborative research with universities, healthcare organizations, agricultural research institutions, government agencies, and environmental organizations globally. Pricing is not publicly disclosed, consistent with a preclinical R&D-stage company. Named historical relationships include NIH, HHS, CMS, VA Medical, and unspecified pharma partners, though the input does not establish whether these are active contracts, past engagements, or background of team members.

The company is registered as a trademark and 100% US-owned corporation, with publicly disclosed government identifiers (UEI X28FBXVY5J98, Cage Code 9CDTO) suggesting potential federal contracting eligibility. No patents, regulatory clearances, certifications, executive team bios, or funding rounds are disclosed in the input data, and the management team roster is empty. The website is built on GoDaddy infrastructure with a single English-language site, a LinkedIn presence, and an email newsletter as primary marketing channels. Substantive evidence of operational scale — payments, signed contracts, employee count detail, named investors — is absent.

Short descriptiontext

TheraSyn Bio is a Massachusetts-based preclinical synthetic biology company developing precision therapeutics through Project Panacea, a breast cancer topical therapy advanced via a joint venture with Rubix LS on an AI-augmented bioscience platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic biology platform, precision bioscience tools, AI-augmented therapeutics, molecular engineering research, translational biotech solutions
Industry2 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Bioscience & Synthetic Biology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Development and Licensing
TypeLicensing Royalties
Description

Development of next-generation precision therapeutics including Project Panacea for breast cancer and women's health, with potential for licensing outcomes to pharmaceutical partners

therasynbio.com
2Platform Services and Partnerships
TypeProfessional Services
Description

Collaborative research services with industry leaders, academic institutions, and strategic partners across healthcare, environmental science, and agriculture sectors

therasynbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TheraSyn Bio operates an AI-augmented Integrated Bioscience Innovation Platform that combines synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational digital development of bioscience research. Its flagship initiative, Project Panacea, is a joint venture with Rubix LS advancing a localized, precision-based topical therapy for breast cancer and women's health. The platform also extends to environmental science and agriscience applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Localized precision-based therapeutic development designed to improve therapeutic efficacy while reducing systemic toxicity
Product overview1 text field

TheraSyn Bio is a digital technology company operating a unified integrated bioscience innovation platform augmented by AI to target precision bioscience. The company offers its core Integrated Bioscience Innovation Platform, which enables AI-powered sample characterization and computational digital development of bioscience research. The platform's flagship initiative is Project Panacea, a therapeutic development program focused on breast cancer and women's health. The platform strategy spans three strategic pillars: Patient Therapies, Environmental Science, and Agriscience, all connected through synthetic biology, AI, and translational research capabilities.

Product and service2 records
1Integrated Bioscience Innovation Platform
2Project Panacea
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint venture collaboration for Project Panacea, TheraSyn Bio's flagship initiative advancing innovative approaches for breast cancer and women's health. This collaboration unites TSB's bioengineering expertise with Rubix LS's extensive real-world patient data insights to create a localized, precision-based treatment that enhances therapeutic efficacy while minimizing systemic toxicity. The venture integrates synthetic biology with patient-centric data analytics for preclinical research evaluating safety, efficacy, and feasibility of a novel topical therapy for breast cancer.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Computational chemistry and biology platform serving pharma and biotech with molecular simulation and AI tools. Overlaps with TheraSyn Bio's AI-augmented bioscience approach but operates at a much broader scale.

TypeDirect peer
Description

AI-driven oncology drug development company using machine learning to identify and develop precision cancer therapies. Comparable in applying AI and patient data analytics to precision oncology.

TypeEmerging player
Description

AI biotech company combining multimodal patient data and AI for drug discovery and development, with oncology focus. Comparable in applying AI to real-world patient data for precision therapeutic development.

TypeBroad incumbent
Description

Cloud-based life sciences R&D platform used for biological data management, molecular design, and lab workflows. Comparable as an integrated bioscience platform serving therapeutic developers.

TypeDirect peer
Description

AI-driven precision medicine company applying computational design to drug discovery, particularly in oncology. Comparable to Project Panacea's AI-driven precision oncology focus.

TypeDirect peer
Description

AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate therapeutic development. Directly comparable to TheraSyn Bio in applying AI and biology to precision therapeutics.

7Tempus AI
TypeBroad incumbent
Description

Precision medicine platform leveraging AI and large real-world clinical/molecular datasets to advance oncology therapeutics. Comparable in combining AI with patient-centric data for precision oncology, similar to the Rubix LS partnership angle.

TypeDirect peer
Description

Synthetic biology platform company engineering organisms for healthcare, agriculture, and industrial applications. Closely matches TheraSyn Bio's synthetic biology platform approach across multiple verticals.

TypeDirect peer
Description

AI-enabled biotech using computational tools and high-dimensional biology to discover and develop precision medicines. Comparable in integrating AI, biology, and translational research pipelines.

TypeEmerging player
Description

AI-powered protein engineering platform for synthetic biology applications. Comparable in combining generative AI with synthetic biology for therapeutic and industrial use cases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TheraSyn Bio

Precision Bioscience & Synthetic Biology Therapeuticstherasynbio.com

TheraSyn Bio is a Massachusetts-based preclinical synthetic biology company developing precision therapeutics through Project Panacea, a breast cancer topical therapy advanced via a joint venture with Rubix LS on an AI-augmented bioscience platform.

What TheraSyn Bio does

TheraSyn Bio (TSB) is a Massachusetts-incorporated, privately held synthetic biology company founded in 2022 and headquartered in Lawrence, near the Cambridge innovation corridor. It operates an Integrated Bioscience Innovation Platform that the company describes as combining synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational bioscience research. The platform spans three stated pillars: Patient Therapies, Environmental Science, and Agriscience. The company's flagship initiative is Project Panacea, a preclinical program developing a localized, topical precision therapy for breast cancer intended to improve therapeutic efficacy while reducing systemic toxicity. Project Panacea is being advanced through a joint venture with Rubix LS, which contributes real-world patient data and clinical research expertise, while TSB contributes bioengineering capabilities. The company is explicitly pre-commercial: no products are approved or generating revenue, no funding rounds are disclosed, and headcount is reported in the 1-10 range.

TheraSyn Bio's commercial posture is enterprise-led and partnership-driven rather than product-sales-driven. Revenue mechanics, as disclosed, contemplate two streams: (i) therapeutic development and licensing, where Project Panacea and successor programs could be licensed to pharmaceutical partners, and (ii) platform services and partnerships, through collaborative research with universities, healthcare organizations, agricultural research institutions, government agencies, and environmental organizations globally. Pricing is not publicly disclosed, consistent with a preclinical R&D-stage company. Named historical relationships include NIH, HHS, CMS, VA Medical, and unspecified pharma partners, though the input does not establish whether these are active contracts, past engagements, or background of team members.

The company is registered as a trademark and 100% US-owned corporation, with publicly disclosed government identifiers (UEI X28FBXVY5J98, Cage Code 9CDTO) suggesting potential federal contracting eligibility. No patents, regulatory clearances, certifications, executive team bios, or funding rounds are disclosed in the input data, and the management team roster is empty. The website is built on GoDaddy infrastructure with a single English-language site, a LinkedIn presence, and an email newsletter as primary marketing channels. Substantive evidence of operational scale — payments, signed contracts, employee count detail, named investors — is absent.

TheraSyn Bio firmographics

Firmographics
Name
TheraSyn Bio
Legal name
TheraSyn Bio Inc
Website
https://therasynbio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
TheraSyn Bio is a Massachusetts-based preclinical synthetic biology company developing precision therapeutics through Project Panacea, a breast cancer topical therapy advanced via a joint venture with Rubix LS on an AI-augmented bioscience platform.
Ownership category
akta.pro rank

TheraSyn Bio industry classification

Industry
Product category
Precision Bioscience & Synthetic Biology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Synthetic biology platform
  • Precision bioscience tools
  • AI-augmented therapeutics
  • Molecular engineering research
  • Translational biotech solutions

Where TheraSyn Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TheraSyn Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Development and Licensing: Development of next-generation precision therapeutics including Project Panacea for breast cancer and women's health, with potential for licensing outcomes to pharmaceutical partners
  2. Platform Services and Partnerships: Collaborative research services with industry leaders, academic institutions, and strategic partners across healthcare, environmental science, and agriculture sectors

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

TheraSyn Bio product offering

Product offering

Core offering

TheraSyn Bio operates an AI-augmented Integrated Bioscience Innovation Platform that combines synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational digital development of bioscience research. Its flagship initiative, Project Panacea, is a joint venture with Rubix LS advancing a localized, precision-based topical therapy for breast cancer and women's health. The platform also extends to environmental science and agriscience applications.

Product overview

TheraSyn Bio is a digital technology company operating a unified integrated bioscience innovation platform augmented by AI to target precision bioscience. The company offers its core Integrated Bioscience Innovation Platform, which enables AI-powered sample characterization and computational digital development of bioscience research. The platform's flagship initiative is Project Panacea, a therapeutic development program focused on breast cancer and women's health. The platform strategy spans three strategic pillars: Patient Therapies, Environmental Science, and Agriscience, all connected through synthetic biology, AI, and translational research capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Integrated Bioscience Innovation Platform
  • Project Panacea

Quantifiable outcome

  • Localized precision-based therapeutic development designed to improve therapeutic efficacy while reducing systemic toxicity

Companies that use TheraSyn Bio

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

TheraSyn Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

TheraSyn Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Rubix LSflagshipStrategic or Co-development PartnerJoint venture collaboration for Project Panacea, TheraSyn Bio's flagship initiative advancing innovative approaches for breast cancer and women's health. This collaboration unites TSB's bioengineering expertise with Rubix LS's extensive real-world patient data insights to create a localized, precision-based treatment that enhances therapeutic efficacy while minimizing systemic toxicity. The venture integrates synthetic biology with patient-centric data analytics for preclinical research evaluating safety, efficacy, and feasibility of a novel topical therapy for breast cancer.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

TheraSyn Bio competitors and assessment

Company assessment

Broad incumbents

  • Schrödinger: Computational chemistry and biology platform serving pharma and biotech with molecular simulation and AI tools. Overlaps with TheraSyn Bio's AI-augmented bioscience approach but operates at a much broader scale.
  • Benchling: Cloud-based life sciences R&D platform used for biological data management, molecular design, and lab workflows. Comparable as an integrated bioscience platform serving therapeutic developers.
  • Tempus AI: Precision medicine platform leveraging AI and large real-world clinical/molecular datasets to advance oncology therapeutics. Comparable in combining AI with patient-centric data for precision oncology, similar to the Rubix LS partnership angle.

Direct peers

  • Lantern Pharma: AI-driven oncology drug development company using machine learning to identify and develop precision cancer therapies. Comparable in applying AI and patient data analytics to precision oncology.
  • Exscientia: AI-driven precision medicine company applying computational design to drug discovery, particularly in oncology. Comparable to Project Panacea's AI-driven precision oncology focus.
  • Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate therapeutic development. Directly comparable to TheraSyn Bio in applying AI and biology to precision therapeutics.
  • Ginkgo Bioworks: Synthetic biology platform company engineering organisms for healthcare, agriculture, and industrial applications. Closely matches TheraSyn Bio's synthetic biology platform approach across multiple verticals.
  • Recursion Pharmaceuticals: AI-enabled biotech using computational tools and high-dimensional biology to discover and develop precision medicines. Comparable in integrating AI, biology, and translational research pipelines.

Emerging players

  • Owkin: AI biotech company combining multimodal patient data and AI for drug discovery and development, with oncology focus. Comparable in applying AI to real-world patient data for precision therapeutic development.
  • Cradle Bio: AI-powered protein engineering platform for synthetic biology applications. Comparable in combining generative AI with synthetic biology for therapeutic and industrial use cases.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

TheraSyn Bio social profiles

Digital presence

TheraSyn Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TheraSyn Bio leadership team

Management profile

Number of profiles

Profiles1 record

TheraSyn Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TheraSyn Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheraSyn Bio

What does TheraSyn Bio do?

TheraSyn Bio operates an AI-augmented Integrated Bioscience Innovation Platform that combines synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational digital development of bioscience research. Its flagship initiative, Project Panacea, is a joint venture with Rubix LS advancing a localized, precision-based topical therapy for breast cancer and women's health. The platform also extends to environmental science and agriscience applications.

Is TheraSyn Bio a public or private company?

TheraSyn Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was TheraSyn Bio founded?

TheraSyn Bio was founded in 2022. It employs 1 to 10 people.

Where is TheraSyn Bio based?

TheraSyn Bio is headquartered in Cambridge, United States, in the North America region.

How does TheraSyn Bio make money?

Two revenue lines are on record. Therapeutic Development and Licensing is the primary driver. The others are platform Services and Partnerships.

Who are TheraSyn Bio's main competitors?

Broad incumbents on record are Schrödinger, Benchling and Tempus AI. Direct peers are Lantern Pharma, Exscientia, Insitro, Ginkgo Bioworks and Recursion Pharmaceuticals. Emerging players are Owkin and Cradle Bio.

Does TheraSyn Bio have an API?

No public API is recorded for TheraSyn Bio.

What industry is TheraSyn Bio in?

TheraSyn Bio's product category is Precision Bioscience & Synthetic Biology Therapeutics. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals